Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03343054
Recruitment Status : Active, not recruiting
First Posted : November 17, 2017
Last Update Posted : July 21, 2020
Sponsor:
Information provided by (Responsible Party):
Pfizer

Tracking Information
First Submitted Date  ICMJE November 11, 2017
First Posted Date  ICMJE November 17, 2017
Last Update Posted Date July 21, 2020
Actual Study Start Date  ICMJE November 30, 2017
Estimated Primary Completion Date June 30, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 5, 2019)
  • Number of participants with Dose-limiting toxicities (DLT) [ Time Frame: Baseline up to 28 days ]
    Number of participants with Dose-limiting toxicities (DLT)
  • Number of Participants With Objective Response [ Time Frame: Baseline up to disease progression or any case of death ]
    OR is defined as a complete response (CR) or partial response (PR) according to RECIST v.1.1. recorded from baseline until disease progression or death due to any cause.
Original Primary Outcome Measures  ICMJE
 (submitted: November 11, 2017)
Number of participants with Dose-limiting toxicities (DLT) [ Time Frame: Baseline up to 28 days ]
Number of participants with Dose-limiting toxicities (DLT)
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 5, 2019)
  • Maximum Observed Plasma Concentration (Cmax) [ Time Frame: 0, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 24, hours post-dose ]
    Maximum Observed Plasma Concentration (Cmax)
  • Area under the Concentration-Time Curve (AUC) [ Time Frame: 0, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 168 hours post-dose ]
    AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.
  • Plasma Decay Half-Life (t1/2) [ Time Frame: 0, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 168 hours post-dose ]
    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
  • Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: 0, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 168 hours post-dose ]
    Time to Reach Maximum Observed Plasma Concentration (Tmax)
  • Objective Response - Number of Participants With Objective Response [ Time Frame: Baseline up to 12 months ]
    OR is defined as a complete response (CR) or partial response (PR) according to RECIST v.1.1. recorded from baseline until disease progression or death due to any cause.
  • Pre-dose Plasma Concentration (Ctrough) [ Time Frame: 0 (pre-dose) on Day 1 of Cycle 2, 3 and 4 ]
    Ctrough is pre-dose concentration during multiple dosing which is observed directly from the actual time-concentration data.
  • Time to tumor Response (TTR) [ Time Frame: From initiation of treatment up to initial objective response ]
    TTR is defined as the time from the first dose date to date of first documentation of OR.
  • Disease Control (DC) [ Time Frame: Baseline up to disease progression or any case of death ]
    DC is defined as CR, PR or SD according to the RECIST version 1.1 recorded in the time period between first dose of study treatment and disease progression or death to any cause.
  • Progression Free Survival (PFS) [ Time Frame: Baseline up to disease progression or any cause of death ]
    PFS is defined as the time from the first dose date to date of first documentation of PD or death due to any cause.
  • Overall Survival (OS) [ Time Frame: Baseline up to any cause of death ]
    OS is defined as the time from the first dose date to date of death due to any cause
Original Secondary Outcome Measures  ICMJE
 (submitted: November 11, 2017)
  • Maximum Observed Plasma Concentration (Cmax) [ Time Frame: 0, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 24, hours post-dose ]
    Maximum Observed Plasma Concentration (Cmax)
  • Area under the Concentration-Time Curve (AUC) [ Time Frame: 0, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 168 hours post-dose ]
    AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.
  • Plasma Decay Half-Life (t1/2) [ Time Frame: 0, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 168 hours post-dose ]
    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
  • Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: 0, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 168 hours post-dose ]
    Time to Reach Maximum Observed Plasma Concentration (Tmax)
  • Objective Response - Number of Participants With Objective Response [ Time Frame: Baseline up to 12 months ]
    OR is defined as a complete response (CR) or partial response (PR) according to RECIST v.1.1. recorded from baseline until disease progression or death due to any cause.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
Official Title  ICMJE A PHASE 1 STUDY OF THE SAFETY, PHARMACOKINETICS AND ANTI-TUMOR ACTIVITY OF TALAZOPARIB, POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
Brief Summary

This is a Phase 1 study which consists of 2 parts; Dose Escalation part and Expansion part.

The dose escalation part is open-label, and evaluates safety, preliminary efficacy and PK of single-agent talazoparib in sequential cohorts of adult patients with advanced solid tumors who are resistant to standard therapy or for whom no standard therapy is available.

In the dose escalation part, up to 18 (minimum 3) patients are expected to be enrolled depending on the observed DLTs.

The expansion part is designed to assess the efficacy, safety and PK of single-agent talazoparib at RP2D determined in the dose escalation part in adult patients with locally advanced or metastatic breast cancer who have deleterious or suspected deleterious germline BRCA1 or BRCA2 mutations.

In the expansion part, a minimum of 17 patients will be enrolled evaluable for the primary endpoint.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Neoplasms
  • Breast Neoplasms
Intervention  ICMJE Drug: talazoparib
Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.
Study Arms  ICMJE Experimental: talazoparib
0.75 mg/day or 1.0 mg/day
Intervention: Drug: talazoparib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: July 20, 2020)
27
Original Estimated Enrollment  ICMJE
 (submitted: November 11, 2017)
18
Estimated Study Completion Date  ICMJE December 28, 2022
Estimated Primary Completion Date June 30, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

[Dose Escalation Part]

Inclusion Criteria:

  • Histological or cytological diagnosis of locally advanced or metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
  • ECOG Performance Status 0 or 1.
  • Adequate Bone Marrow, Renal and Liver Function.

Exclusion Criteria:

  • Patients with known symptomatic brain metastases requiring steroids.
  • Current use of a strong P-gp inhibitor, strong P-gp inducer, or strong inhibitor of BCRP within 1 week or 5 half lives which ever is longer prior to the first dose of study treatment.
  • Fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception.

[Dose Expansion Part]

Inclusion Criteria:

  • Histologically or cytologically confirmed carcinoma of the breast.
  • Locally advanced breast cancer that is not amenable to curative radiation or surgery and/or metastatic disease.
  • Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA1 or BRCA2 mutation by Myriad Genetics' BRACAnalysis CDx test.
  • No more than 3 prior chemotherapy-inclusive regimens for locally advanced or metastatic disease.
  • Have measurable lesion by the RECIST v.1.1.
  • ECOG Performance Status 0-2.
  • Adequate Bone Marrow, Renal and Liver Function.

Exclusion Criteria:

  • First-line locally advanced or metastatic breast cancer with no prior neoadjuvant and adjuvant chemotherapy.
  • Prior treatment with a PARP inhibitor.
  • Objective disease progression while receiving platinum chemotherapy administered for locally advanced or metastatic disease.
  • HER2 positive breast cancer.
  • Active inflammatory breast cancer.
  • Central nervous system (CNS) metastases.
  • Current or anticipated use within 7 days prior to the first dose of study treatment, or anticipated use during the study of strong P-gp inhibitors.
  • Fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 20 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03343054
Other Study ID Numbers  ICMJE C3441030
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP